None listed
Conditions
Brief summary
Omega-3 fatty acids are widely consumed as dietary supplements and are known to have beneficial effects on health. However, it is not well understood how different doses of omega-3 supplementation change the composition and function of human immune cells. This study will compare two doses of omega-3 supplementation in healthy adults over a 4-week period. Blood samples collected before, during and after supplementation will be used to examine how omega-3 fatty acids are incorporated into immune cells and whether this influences their biological function and responses to oxidative stress. The findings will improve our understanding of how dietary omega-3 fatty acids influence the human immune system and provide important information for future studies investigating omega-3 supplementation in health and disease.
Interventions
High-dose omega-3 fatty acid supplementation (Arm 2)
Participants will receive oral omega-3 polyunsaturated fatty acid (n-3 PUFA; approximately 4800 mg/day) supplementation containing eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) for 4 weeks. Participants will consume four capsules daily with food. The study supplement is a Therapeutic Goods Administration (TGA)-registered fish oil preparation. Adherence will be assessed by capsule counts and participant self-report.
Sponsors
Baker Heart and Diabetes Institute
Study design
Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Treatment
Masking
Blinded (masking used) (Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
All
Age
18 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
Healthy male and female volunteers aged 18–45 years with a body mass index (BMI) between 18.5 and 28 kg/m². Participants must be willing and able to provide written informed consent, comply with all study procedures, attend study visits, and consume the allocated omega-3 supplement for 4 weeks.
Exclusion criteria
Individuals with a history of cardiovascular disease, diabetes, cancer, chronic inflammatory or autoimmune disease, liver or kidney disease, or other clinically significant medical conditions. Current use of omega-3 supplements or medications known to influence lipid metabolism or immune function, allergy to fish or fish oil, pregnancy or breastfeeding, current smoking or excessive alcohol consumption, participation in another clinical trial within the previous 30 days, or any condition that, in the opinion of the investigators, would make participation unsafe or interfere with study completion.
Outcome results
None listed